HUMA vs IART
HUMA: Humacyte engineers acellular tissue-based blood vessels (ATEVs) for vascular access and other applications, with its lead product Symvess in late-stage clinical development. IART: Integra LifeSciences is a medical technology company specializing in regenerative medicine, neurosurgery, and advanced surgical instrumentation.
Side-by-side fundamentals
| Metric | HUMA | IART | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $0.64 | $18.82 | |
| Market cap as of 2026-07-23 | $174M | $1.5B | |
| PEG as of 2026-07-23 | n/a | -0.00 | |
| Net margin as of 2026-07-23 | -3494.6% | -30.1% | IART higher |
| Gross margin as of 2026-07-23 | -563.6% | +57.1% | IART higher |
| Operating margin as of 2026-07-23 | -6205.7% | -28.4% | IART higher |
| ROE as of 2026-07-23 | -1278.9% | -47.6% | IART higher |
| ROA as of 2026-07-23 | -85.4% | -13.7% | IART higher |
| Debt / equity as of 2026-07-23 | 5.67 | 1.79 | IART lower |
| Revenue growth (YoY) as of 2026-07-23 | +231.7% | +1.2% | HUMA higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +1.6% | |
| Beta as of 2026-07-23 | 2.56 | 1.21 | |
| 1-year return as of 2026-07-22 close | -70.8% | +67.2% | IART higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.